NCT04246541View on ClinicalTrials.gov

Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

September 12, 2021

Study Completion Date

September 12, 2021

Conditions
Meniscus Tear, TibialPain, PostoperativePostoperative ComplicationsKetorolac Adverse ReactionOpioid Use
Interventions
DRUG

Ketorolac

Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.

DRUG

Oxycodone-Acetaminophen

Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.

Trial Locations (1)

44106

UH Cleveland Medical Center, Cleveland

All Listed Sponsors
lead

University Hospitals Cleveland Medical Center

OTHER

NCT04246541 - Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery | Biotech Hunter | Biotech Hunter